Race Oncology Ltd
ASX:RAC

Watchlist Manager
Race Oncology Ltd Logo
Race Oncology Ltd
ASX:RAC
Watchlist
Price: 2.74 AUD 0.37% Market Closed
Market Cap: AU$489.5m

Operating Margin

-598.1%
Current
Improving
by 1 272.3%
vs 3-y average of -1 870.3%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-598.1%
=
Operating Income
AU$-4.7m
/
Revenue
AU$788.4k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-598.1%
=
Operating Income
AU$-4.7m
/
Revenue
AU$788.4k

Peer Comparison

Country Company Market Cap Operating
Margin
AU
Race Oncology Ltd
ASX:RAC
474.3m AUD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
186.7B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
162.9B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.8B USD
Loading...

Market Distribution

Lower than 71% of companies in Australia
Percentile
29th
Based on 3 951 companies
29th percentile
-598.1%
Low
-14 949 200% — -526.4%
Typical Range
-526.4% — 6.1%
High
6.1% — 145 596.9%
Distribution Statistics
Australia
Min -14 949 200%
30th Percentile -526.4%
Median -25.2%
70th Percentile 6.1%
Max 145 596.9%

Race Oncology Ltd
Glance View

Market Cap
489.5m AUD
Industry
Biotechnology

Race Oncology Ltd. is a precision oncology company, with the phase 2/3 cancer drug, Bisantrene, which is a potent small molecule inhibitor of the Fatso (FTO) protein. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-07-13. Bisantrene is a small molecule inhibitor of the fat mass and obesity associated (FTO) protein. The firm is targeting the use of Bisantrene in melanoma and clear cell renal cell carcinoma (kidney cancer), both frequent FTO-driven cancers. Race also has clinical data for the use of Bisantrene in Acute Myeloid Leukaemia (AML), Breast and Ovarian cancers.

RAC Intrinsic Value
0.4 AUD
Overvaluation 85%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-598.1%
=
Operating Income
AU$-4.7m
/
Revenue
AU$788.4k
What is Race Oncology Ltd's current Operating Margin?

The current Operating Margin for Race Oncology Ltd is -598.1%, which is above its 3-year median of -1 870.3%.

How has Operating Margin changed over time?

Over the last 3 years, Race Oncology Ltd’s Operating Margin has increased from -20 685% to -598.1%. During this period, it reached a low of -20 685% on Jun 30, 2022 and a high of -598.1% on Jun 30, 2025.

Back to Top